---
document_datetime: 2023-09-21 17:58:37
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/tritanrix-hepb-epar-procedural-steps-taken-authorisation_en.pdf
document_name: tritanrix-hepb-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5248228
conversion_datetime: 2025-12-29 20:07:34.667895
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## I BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the Dossier

The  company  SmithKline  Beecham  Biologicals  S.  A.,  Belgium,  submitted  in  December  1994  an application to all EU Member States for Tritanrix HepB through the Concertation Procedure (No. 93). In  application  to  Article  2  of  Directive  93/41/EEC,  on  1  January  1995,  the  company  SmithKline Beecham  Biologicals  S.  A.,  Belgium,  transferred  to  the  European  Agency  for  the  Evaluation  of Medicinal Products and into the new centralised procedure the application for marketing authorisation for  Tritanrix  HepB,  falling  within  the  scope  of  Part  A  of  the  Annex  to  Council  Regulation  (EEC) 2309/93 of 22 July 1993.

- A hearing  with  the  company  was  agreed  by  the  CPMP  Members  to  take  place  in  December 1995 to discuss outstanding questions.

Medicinal product no longer authorised The Rapporteur and Co-Rapporteurs appointed by CPMP were: Rapporteur: Dr. Pieter Neels Co-Rapporteur: Dr. Manfred Haase Licensing Status: Tritanrix HepB is licensed in several non EU countries. 2. Steps Taken for the Assessment of the Product · The Rapporteur's initial full assessment report was circulated to all Members of the CPMP on 31 January 1995. · The  CPMP,  in  its  meeting  on  13-14  March  1995,  discussed  extensively  the  different  health protection  policies  in  force  in  the  EU  member  states  with  respect  to  the  use  of  combined vaccines and vaccination schedules. · The  CPMP  ad  hoc  Biotechnology  Working  Party  during  its  meeting  on  3-4  April  1995 circulated  a  draft  list  of  questions.  The  possibility  of  confusion  over  the  trade  name  of  the product with other existing vaccines was also considered. · The CPMP, in its meeting on 26-27 April 1995, finalised the list of questions to be sent to the company. · The  CPMP  consolidated  list  of  questions  was  sent  to  the  company  on  3  May  1995  and  the running time of the evaluation procedure was stopped. · The company submitted their responses report to the consolidated CPMP list of comments on 28 September 1995. · The response assessment report was circulated to all CPMP Members by the Rapporteur on 16 November 1995. · The  company  submitted  on  16  November  1995,  corrections  made  to  the  responses  report submitted on 28 September 1995. · The  CPMP  in  its  meeting  on  21-22  November  1995,  considered  outstanding  issues  to  be addressed by the company.

- An Annex to the response assessment report, dealing with the corrections made by the company to  the  above  mentioned  consolidated  response,  was  circulated  by  the  Rapporteur  on  29 November 1995.

<div style=\"page-break-after: always\"></div>

- A meeting was held between the EMEA, the Rapporteur and the company on the 18 December 1995 to discuss the outstanding questions raised at the November CPMP meeting and to prepare the responses to be presented at the hearing during the CPMP meeting on 19-20 December 1995.

<!-- image -->

Medicinal product no longer authorised · The company presented the responses to the CPMP questions during a hearing on 19  December  1995.  The  company  agreed  to  stop  the  clock  until  the  written  responses  were circulated to all the CPMP members. · The CPMP during its meeting on 16-18 January 1996, discussed and agreed to have a break-out session in the February CPMP meeting, with an expert from the WHO to discuss further the technical  issues  related  to  the  vaccine  and  its  therapeutic  interest  in  other  parts  of  the  world outside the EU. Furthermore the Commission was asked to invite the WHO representative to the plenary  meeting  of  the  CPMP  in  February,  in  order  to  present  an  overview  of  the  WHO's 'Children's Vaccine Initiative' (CVI). · The additional data presented by the company at the hearing in December 1995 was circulated to the CPMP members on 18 January 1996. · The Rapporteur circulated the assessment report on the additional data on 31 January 1996. · During the CPMP meeting on 13-15 February 1996, a break-out session with an expert from the WHO took  place  on  13  February  1996,  to  discuss  the  reactogenicity  profiles  of  DTPw  and hepatitis B vaccines as separate injections and in the combination product under review. · On  14  February  1996,  representatives  of  the  WHO  and  CVI  (Children's  Vaccine  Initiative) presented to the CPMP an overview of WHO's 'Children's Vaccines Initiative', as well as their recommendations and reasons for the need for such a combined vaccine, especially on a global level. · On 19 February 1996, the company as requested by the CPMP in its meeting in February 1996, circulated supplementary information on the reactogenicity profile of marketed DTPw vaccines, updated specifications and new amended text for the SPC, Package User Leaflet and labelling. · The  Rapporteur's  assessment  reports  on  the  supplementary  information  provided  by  the company were circulated on 29 February 1996 (on quality issues, SPC, PUL and labelling) and on 6 March 1996 (reactogenicity profile). · During the CPMP meeting on 12-14 March 1996, final discussions and subsequent agreement on texts for SPC, Package Labelling and Package Leaflet took place, resulting in the adoption of two positive Opinions for the monodose and multidose presentations of Tritanrix HepB.